Drug Trial Radar · NCT07890714
A Study of Dato-DXd in Participants With Solid Tumors [TROPION-PanTumor04 (TP04)]
Last checked: Nov 19, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
268
Planned (sponsor's estimate)
Start
Oct 16, 2026
Primary completion
Sep 30, 2029
Study completion Jan 31, 2030
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Oct 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is designed to assess the safety, tolerability, and antitumor activity of Datopotamab Deruxtecan (Dato-DXd) combined with other anticancer agents or as monotherapy in participants with solid tumors.
Conditions
- Urothelial Cancer
- Non-small Cell Lung Cancer
Interventions
Dato-DXdDrug
Dato-DXd will be administered as an IV infusion.
Enfortumab Vedotin (EV)Drug
EV will be administered as IV infusion.
PembrolizumabDrug
Pembrolizumab will be administered as an IV infusion.
OlomorasibDrug
Olomorasib will be administered as oral capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Number of Participants With Dose-limiting Toxicities (DLTs)Time frame: During Cycle 1 (cycle length = 21 days)
- Phase 1: Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Up to approximately 2.9 years
- Phase 2: Objective Response Rate (ORR) as Assessed by InvestigatorTime frame: Up to approximately 2.9 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
TCVGH (Taichung Veterans General Hospital)
Taichung, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.